

## **List of Supplementary Information**

### Supplementary Text

- Supplementary note on Hox13 mouse mutant phenotype
- Link to Supplementary Movies

### Supplementary Figures 1-6

### Supplementary Tables 1-6


## Supplementary Text

### Supplementary note on Hox13 mouse mutant phenotype

The work of Economides and colleagues, genetically deleting *Hoxb13* in the mouse<sup>16</sup>, demonstrated an overgrowth phenotype of the caudal spinal cord and caudal/tail vertebrae. Based on image 2B in this publication, subsequent publications have cited this phenotype as additional tail elements, not solely larger elements. However, even on isogenic mouse backgrounds, we and others have demonstrated variation in tail vertebrae number +/-1 around a mean, thus it is critical to perform appropriate quantification to validate any increase in total vertebral number. Quantification was not performed in Economides et al., and thus we have not cited this work as a known mechanism that increases vertebral number. Similarly, analysis of *Hoxc13* mouse mutants was not able to quantify an increase in tail vertebral number over the variation seen between individuals<sup>17</sup>, and further analysis of both mouse mutants is required before conclusions are drawn.


### Link to Supplementary Movies

<https://figshare.com/s/78383c7beb9b85c959bf>




**Supplementary Figure 1: Characterisation of pluripotent stem cell tools before and during *in vitro* differentiation to axial progenitors.**

**a**, *In vivo* teratoma assay of WT and miR-196-triple Knockout (TKO) induced pluripotent stem cell (iPSC) lines generated for these studies confirms both cell lines are competent to produce derivatives of all three germ layers. **b**, Schematic of 7-day (D= day) *in vitro* differentiation protocol employed. **c**, Comparison of axial identity and cell lineage marker gene expression between WT embryonic stem cell (ESC) and WT iPSC lines used in these studies. Quantitative PCR (qPCR) analysis of select genes including anterior (*Hoxb1*), trunk (*Hoxb8*, *Hoxc8*) and posterior (*Hoxd12*) *Hox* genes, NMP/early mesoderm marker *T-Brachyury* (*T-Bra*) and the neural markers *Sox1* and *Sox2* showed near-identical expression kinetics for all genes assessed over the course of differentiation. Plotted is the  $\log_2(\text{fold change})$  relative to Day 0, 3 biological replicates for each condition and day, fitted with a curve using local polynomial regression fitting. Source data are provided as a Source Data file.



**Supplementary Figure 2: Inhibition of retinoic acid (RA) receptors in utero further changes axial formulae and together with *Gdf11* controls the anterior expression boundary of *Hoxc6*.**



**a**, Representative Embryonic day (E)18.5 skeletal preparations across *miR-196* and *Gdf11* individual and compound mouse mutant skeletal phenotypes focusing on the presacral vertebral column following AGN193109 treatment. C= cervical; T= thoracic; L= lumbar. **b**, Whole mount *in situ* hybridisation (WISH) analysis of *Hoxc6* expression in WT, *Gdf11*<sup>+/-</sup> and *Gdf11*<sup>-/-</sup> E10.5 embryos exposed to AGN193109 in utero. The combined decrease in *Gdf11* and RA signalling led to a posterior shift in the rostral boundary of *Hoxc6* expression by one somite. pv= prevertebra.




**Supplementary Figure 3: Validation of altered *Hox* gene expression identified using Fluidigm, with spatial context provided by *in situ* hybridisation.**

Spatial characterisation of selected posterior *Hox* genes by whole mount *in situ* hybridisation of E10.5 WT and *Gdf11*<sup>-/-</sup> embryos confirms quantitative changes identified by Fluidigm PCR

*Hoxa11* expression is cleared from the tail bud in WT at this stage of development, however expression extends to the tail tip in *Gdf11*<sup>-/-</sup> embryos. All other posterior *Hox* genes assessed showed a significant reduction or complete lack of expression in *Gdf11*<sup>-/-</sup> embryos when compared to WT.




Founder lineage	Copy number (ddPCR: Hoxd12)	Axial Phenotype
ET51	6	T13 reduced, 5 Lumbar, 58 Total
ET51	4	T13 reduced, 5 Lumbar, 59 Total
ET51	6	T13 reduced, 5 Lumbar, 60 Total
ET51	4	5 Lumbar, 59 Total
ET51	4	5 Lumbar, 59 Total
ET51	4	5 Lumbar, 60 Total
ET34	4	5 Lumbar, 60 Total
ET34	4	5 Lumbar, 60 Total
ET34	4	5 Lumbar, 61 Total
ET34	3	5 Lumbar, 61 Total
Wildtype	2	6 Lumbar, 61 Total



**Supplementary Figure 4: *In vivo* characterisation of *Hoxd11*<sup>OE</sup> and *Hoxd12*<sup>OE</sup> transgenic mouse lines driven by *Cdx2* upstream regulatory elements.**

**a-b**, Characterisation of F1 embryos confirmed germline transmission in one *Hoxd11*<sup>OE</sup> (OE= overexpressor) **a**, and two *Hoxd12*<sup>OE</sup> **b**, mouse lines. Whole mount *in situ* hybridisation characterisation of each respective *Hox* gene confirmed transgene expression, with slightly precocious activation and increased levels of *Hox* expression observed in transgene-positive



embryos relative to WT. **c**, Embryonic day (E)18.5 skeletal analysis of *Hoxd11<sup>OE</sup>* transgenic allele cross-bred with the *Gdf11* mutant line revealed similar changes in the presacral column as seen with the *Hoxd12<sup>OE</sup>* transgenic allele. C= cervical; T= thoracic; L= lumbar. **d-f**, Quantitative differences in *Hoxd12* copy number correlate with phenotypic variation in axial formulae. **d**, Quantification of total vertebral number within progeny of individual *Hoxd12<sup>OE</sup>* founder lines. Relative to WT, *Hoxd12<sup>OE</sup>* founder line ET51 embryos displayed a significant decrease in total vertebral number (TVN). In *Hoxd12<sup>OE</sup>* founder line ET34 embryos, a trend towards reduced TVN was observed but was not significant. **e**, Correlation of axial formulae and *Hoxd12* copy number for multiple embryos of each founder line indicates that quantitative differences in *Hoxd12* expression levels underlie the phenotypic variation observed. **f**, Quantification of TVN in *Gdf11<sup>+/-</sup>* embryos, with or without two independent *Hoxd12<sup>OE</sup>* founder lines (ET34 and ET51). **d, f**, Raw data is presented in the upper plot (vertical error bar = mean and standard deviation). Mean differences relative to shared reference genotype (here WT or *Gdf11<sup>+/-</sup>*) are presented in the lower plot as bootstrap sampling distributions. Each mean difference is depicted as a dot and 95% confidence interval is indicated by the ends of the vertical error bar. n refers to the number of individual animals used for this analysis. Source data are provided as a Source Data file.



**Supplementary Figure 5: Restoration of posterior Hox expression in *Gdf11*<sup>-/-</sup> embryos supports outgrowth of tail-like structures at mid-gestation.**

**a**, Frequency of observed tail phenotypes across all E12.5 and E13.5 *Gdf11*<sup>-/-</sup>, *Gdf11*<sup>-/-</sup>; *Hoxd11*<sup>OE</sup> and *Gdf11*<sup>-/-</sup>; *Hoxd12*<sup>OE</sup> embryos. Source data are provided as a Source Data file. **b**, Whole-mount *in situ* hybridisation of somite marker *Uncx4.1* in E12.5 WT, *Gdf11*<sup>-/-</sup> and *Gdf11*<sup>-/-</sup>; *Hoxd12*<sup>OE</sup> embryos, confirming segmented *Uncx4.1*+ tissue forms in the ventral tail of *Gdf11*<sup>-/-</sup>; *Hoxd12*<sup>OE</sup>. **c**, Embryonic day (E)18.5 skeletal comparison. Caudal truncation in *Gdf11*<sup>-/-</sup>; *Hoxd12*<sup>OE</sup> embryos was commonly observed immediately after the last sacral element, whereas numerous post-sacral elements commonly formed in *Gdf11*<sup>-/-</sup> embryos.





**Supplementary Figure 6: Histological analysis reveals molecular, cellular and tissue-level alterations in *Gdf11*<sup>-/-</sup> and *Gdf11*<sup>-/-</sup>;*Hoxd12*<sup>OE</sup> embryos.**

**a**, Histological analysis of tail phenotypes in E12.5 WT (n=1) (i-iv), *Gdf11*<sup>-/-</sup> (n=2) (v-viii) and *Gdf11*<sup>-/-</sup>;*Hoxd12*<sup>OE</sup> (n=4) (ix-xii) mouse embryos. Serial sagittal sectioning of the embryos presented in whole-mount (Fig. 4a), stained for Foxa2 (red), Sox2 (green) and DAPI (blue). Arrowhead indicates the position of the notochord in all genotypes. Asterisk highlights Sox2+ cells trapped within Foxa2+ cells in *Gdf11*<sup>-/-</sup> embryos. Sox2+;Foxa2+ co-expression is observed in cells at the distal tip on the tailgut in *Gdf11*<sup>-/-</sup>;*Hoxd12*<sup>OE</sup> embryos. gt= genital tubercle, cl= cloacal cavity, NT= neural tube, tg= tailgut. n refers to the number of individual animals used for this analysis. **b**, Serial section of ventral tail in Fig. 4c showing the *Gdf11*<sup>-/-</sup>;*Hoxd12*<sup>OE</sup> tailbud at E12.5. Co-staining for Sox2 (green) and Foxa2 (red) identified single positive cells of either marker and dual positive cells (n=3). All sections are stained for DAPI (blue), arrowhead indicates notochord. n refers to the number of individual animals used for this analysis.

## Supplemental Tables

### Supplementary Table 1

Skeletal analysis of wild-type, Gdf11-/+ and Gdf11 -/- mice with or without at least five miR-196 alleles deleted.													
	Wildtype		TKO*		Gdf11-/+		Gdf11-/+ ,TKO*		Gdf11-/-		Gdf11-/-, TKO*		
	n	%	n	%	n	%	n	%	n	%	n	%	
<b>Presacral vertebrae**</b>													
25	4	7	-		-		-		-		-		
26	53	93	1	3	2	3	-		-		-		
27	-		32	97	62	95	1	6	-		-		
28	-		-		1	2	6	35	-		-		
29	-		-		-		10	59	-		-		
33	-		-		-		-		3	9	-		
34	-		-		-		-		27	84	-		
35	-		-		-		-		2	6	-		
37	-		-		-		-		-		1	25	
39	-		-		-		-		-		3	75	
<b>Vertebral pattern</b>													
C7 T13 L5	4	7	-		-		-		-		-		
C7 T13 L6	53	93	1	3	1	2	-		-		-		
C7 T14 L6	-		11	33	60	92	1	6	-		-		
C7# T14 L7	-		-		1	2	-		-		-		
C7 T14 L6***	-		-		1	2	-		-		-		
C7 T15 L5	-		21	64	1	2	-		-		-		
C7 T15 L6***	-		-		1	2	-		-		-		
C7 T15 L6	-		-		-		4	24	-		-		
C7 T15 L7	-		-		-		1	6	-		-		
C7 T16 L5	-		-		-		2	12	-		-		
C7 T16 L6	-		-		-		7	41	-		-		
C7 T17 L5	-		-		-		2	12	-		-		
C7 T18 L8	-		-		-		-		1	3	-		
C7 T18 L9	-		-		-		-		22	69	-		
C7 T18 L9***	-		-		-		-		2	6	-		
C7 T18 L10***	-		-		-		-		3	9	-		
C7 T18**** L9	-		-		-		-		1	3	-		
C7 T19**** L9	-		-		-		-		1	3	-		
C7 T19**** L9***	-		-		-		-		1	3	-		
C7 T19**** L10***	-		-		-		-		1	3	-		
C7 T21 L9	-		-		-		-		-		1	25	
C7 T22 L10	-		-		-		-		-		2	50	
C7 T23 L9	-		-		-		-		-		1	25	

\*Only mice with at least five miR-196 knock-out alleles included. \*\*Vertebrae that had lumbar characteristics on one side and sacral characteristics on the other were scored as sacral. \*\*\* Most posterior lumbar element shows lumbar characteristics on one side and sacral characteristics on the other. \*\*\*\* Most posterior thoracic element shows malformed/reduced ribs. # C7 shows thoracic characteristics on one side and cervical characteristics on the other

## Supplementary Table 2

Skeletal analysis of wild-type, Gdf11<sup>-/+</sup> and Gdf11<sup>-/-</sup> mice with and without at least five miR-196 alleles deleted - treated with 0.8mg/kg AGN193109 via oral gavage of pregnant mothers at E7.5/E8.5/E9.5.

	Wildtype + AGN193109		TKO + AGN193109		Gdf11 <sup>-/+</sup> + AGN193109		Gdf11 <sup>-/+</sup> , TKO + AGN193109		Gdf11 <sup>-/-</sup> + AGN193109		Gdf11 <sup>-/-</sup> , TKO* + AGN193109	
	n	%	n	%	n	%	n	%	n	%	n	%
<b>Presacral vertebrae**</b>												
26	6	67	-	-	-	-	-	-	-	-	-	-
27	3	33	1	17	5	42	-	-	-	-	-	-
28	-	-	3	50	7	58	-	-	-	-	-	-
29	-	-	2	33	-	-	1	11	-	-	-	-
30	-	-	-	-	-	-	8	89	-	-	-	-
33	-	-	-	-	-	-	-	-	3	50	-	-
34	-	-	-	-	-	-	-	-	3	50	-	-
37	-	-	-	-	-	-	-	-	-	-	1*	50
40	-	-	-	-	-	-	-	-	-	-	1	50
<b>Vertebral pattern</b>												
C6 T16*** L5	-	-	1	17	-	-	-	-	-	-	-	-
C6/7 T15*** L6	-	-	1	17	-	-	-	-	-	-	-	-
C7 T13 L6	2	22	-	-	-	-	-	-	-	-	-	-
C7 T13*** L6	4	44	-	-	-	-	-	-	-	-	-	-
C7 T14 L6	2	22	-	-	2	17	-	-	-	-	-	-
C7 T14*** L6	1	11	-	-	2	17	-	-	-	-	-	-
C7 T15*** L5	-	-	-	-	1	8	-	-	-	-	-	-
C7 T15 L6	-	-	-	-	1	8	-	-	-	-	-	-
C7 T15*** L6	-	-	1	17	1	8	-	-	-	-	-	-
C7 T16 L5	-	-	1	17	-	-	-	-	-	-	-	-
C7 T16*** L6	-	-	1	17	-	-	1	11	-	-	-	-
C7 T16*** L7	-	-	-	-	-	-	3	33	-	-	-	-
C7 T17*** L6	-	-	-	-	-	-	4	44	-	-	-	-
C7 T18*** L8	-	-	-	-	-	-	-	-	1	17	-	-
C7 T21 L9	-	-	-	-	-	-	-	-	-	-	1*	50
C7 T22 L11	-	-	-	-	-	-	-	-	-	-	1	50
C7/8 T14 L6	-	-	-	-	3	25	-	-	-	-	-	-
C7/8 T17 L8	-	-	-	-	-	-	-	-	1	17	-	-
C8 T14 L6	-	-	-	-	1	8	-	-	-	-	-	-
C8 T14*** L6	-	-	-	-	1	8	-	-	-	-	-	-
C8 T15*** L6	-	-	1	17	-	-	-	-	-	-	-	-
C8 T16*** L6	-	-	-	-	-	-	1	11	-	-	-	-
C8 T17 L8	-	-	-	-	-	-	-	-	1	17	-	-
C8 T17 L9	-	-	-	-	-	-	-	-	2	33	-	-
C8 T17*** L8	-	-	-	-	-	-	-	-	1	17	-	-

\*Mouse with five (out of six) miR-196 alleles knocked out included. \*\*Vertebrae that had lumbar characteristics on one side and sacral characteristics on the other were scored as sacral. \*\*\* Most posterior thoracic element shows malformed ribs.

### Supplementary Table 3

Skeletal analysis of wild-type, Gdf11 <sup>+/+</sup> and Gdf11 <sup>-/-</sup> mice overexpressing either Hoxd11 or Hoxd12 under the Cdx2-Promoter																
	Gdf11 <sup>+/+</sup>		Gdf11 <sup>+/+</sup> , Cdx2P- Hoxd11		Gdf11 <sup>+/+</sup> , Cdx2P- Hoxd12		Gdf11 <sup>-/-</sup>		Gdf11 <sup>-/-</sup> , Cdx2P- Hoxd11		Gdf11 <sup>-/-</sup> , Cdx2P- Hoxd12		Gdf11 <sup>-/-</sup> , Cdx2P- Hoxd11		Gdf11 <sup>-/-</sup> , Cdx2P- Hoxd12	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
<b>Presacral vertebrae *</b>																
25	4	7	15	100	15	94	-	-	-	-	-	-	-	-	-	-
26	53	93	-	-	1	6	2	3	23	96	21	81	-	-	-	-
27	-	-	-	-	-	-	62	95	1	4	5	19	-	-	-	-
28	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-
32	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	9
33	-	-	-	-	-	-	-	-	-	-	-	-	3	9	7	58
34	-	-	-	-	-	-	-	-	-	-	-	-	27	84	5	42
35	-	-	-	-	-	-	-	-	-	-	-	-	2	6	-	-
<b>Vertebral pattern</b>																
C7 T13 L5	4	7	6	40	11	69	-	-	-	-	-	-	-	-	-	-
C7 T13** L5	-	-	9	60	3	19	-	-	-	-	-	-	-	-	-	-
C7 T13** L6***	-	-	-	-	1	6	-	-	-	-	-	-	-	-	-	-
C7 T13 L6	53	93	-	-	1	6	1	2	-	-	-	-	-	-	-	-
C7 T14 L6	-	-	-	-	-	-	60	92	1	4	5	19	-	-	-	-
C7# T14 L7	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-
C7 T14 L6***	-	-	-	-	-	-	1	2	-	-	4	15	-	-	-	-
C7 T15 L5	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-
C7 T15 L6***	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-
C7 T14 L5	-	-	-	-	-	-	-	-	12	50	4	15	-	-	-	-
C7 T14** L5	-	-	-	-	-	-	-	-	11	46	11	42	-	-	-	-
C7 T14** L6***	-	-	-	-	-	-	-	-	-	-	2	8	-	-	-	-
C7 T17 L9	-	-	-	-	-	-	-	-	-	-	-	-	-	1	8	-
C7 T18 L8	-	-	-	-	-	-	-	-	-	-	-	-	1	3	2	17
C7 T18 L9	-	-	-	-	-	-	-	-	-	-	-	-	22	69	5	42
C7 T18 L9***	-	-	-	-	-	-	-	-	-	-	-	-	2	6	1	8
C7 T18 L10***	-	-	-	-	-	-	-	-	-	-	-	-	3	9	-	2
C7 T18** L9	-	-	-	-	-	-	-	-	-	-	-	-	1	3	-	-
C7 T18 L8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
C7 T18** L8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3
C7 T18** L8***	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
C7 T18** L9***	-	-	-	-	-	-	-	-	-	-	-	-	-	3	25	1
C7 T19** L9	-	-	-	-	-	-	-	-	-	-	-	-	1	3	-	-
C7 T19** L9***	-	-	-	-	-	-	-	-	-	-	-	-	1	3	-	-
C7 T19** L10***	-	-	-	-	-	-	-	-	-	-	-	-	1	3	-	-

\* Vertebrae that had lumbar characteristics on one side and sacral characteristics on the other were scored as sacral. \*\* Most posterior thoracic element shows malformed/reduced ribs. \*\*\* Most posterior lumbar element shows lumbar characteristics on one side and sacral characteristics on the other. # C7 shows thoracic characteristics on one side and cervical characteristics on the other

**Supplementary Table 4**

**Unpaired mean differences in total vertebral number counts**

<b>Genotypes compared</b>	<b>Unpaired mean difference</b>	<b>[Confidence interval width: lower bound; upper bound]</b>
WT and TKO	1.1	[95.0%CI: 0.72, 1.43]
WT and Gdf11 <sup>+/-</sup>	3.56	[95.0%CI: 3.28, 3.82]
WT and TKO; Gdf11 <sup>+/-</sup>	5.13	[95.0%CI: 4.52, 5.58]
WT and WT +AGN	1.44	[95.0%CI 1.22, 1.62]
TKO and TKO +AGN	2.01	[95.0%CI 1.35, 3.41]
Gdf11 <sup>+/-</sup> and Gdf11 <sup>+/-</sup> +AGN	1.24	[95.0%CI 0.789, 1.77]
TKO; Gdf11 <sup>+/-</sup> and TKO; Gdf11 <sup>+/-</sup> +AGN	1.81	[95.0%CI 1.17, 2.75]
WT and Hoxd11 <sup>OE</sup>	-0.417	[95.0%CI -0.751, -0.0714]
WT and Hoxd12 <sup>OE</sup>	-0.81	[95.0%CI -1.28, -0.432]
Gdf11 <sup>+/-</sup> and Gdf11 <sup>+/-</sup> ;Hoxd11 <sup>OE</sup>	-0.476	[95.0%CI -0.875, -0.195]
Gdf11 <sup>+/-</sup> and Gdf11 <sup>+/-</sup> ;Hoxd12 <sup>OE</sup>	-0.803	[95.0%CI -1.13, -0.451]
WT and Hoxd12 <sup>OE</sup> (ET34)	-0.378	[95.0%CI -0.689, 0.0222]
WT and Hoxd12 <sup>OE</sup> (ET51)	-1.46	[95.0%CI -1.99, -0.962]
Gdf11 <sup>+/-</sup> and Gdf11 <sup>+/-</sup> ;Hoxd12 <sup>OE</sup> (ET34)	-0.222	[95.0%CI -0.678, 0.222]
Gdf11 <sup>+/-</sup> and Gdf11 <sup>+/-</sup> ;Hoxd12 <sup>OE</sup> (ET51)	-1.36	[95.0%CI -1.71, -1.13]

## Supplementary Table 5

### Taqman Probes used for Biomark Fluidigm

Gene target	Probe ID	Gene target	Probe ID
<i>Gapdh</i>	Mm03302249_g1	<i>Hoxb6</i>	Mm00433970_m1
<i>Gapdh</i>	Mm99999915_g1	<i>Hoxb7</i>	Mm00650702_m1
<i>B-actin</i>	Mm00446971_m1	<i>Hoxb8</i>	Mm00439368_m1
<i>Ubc</i>	Mm01205647_g1	<i>Hoxb9</i>	Mm01700220_m1
<i>Tbp</i>	Mm02525934_g1	<i>Hoxc10</i>	Mm01305933_m1
<i>Hoxa1</i>	Mm00439359_m1	<i>Hoxc11</i>	Mm01305934_m1
<i>Hoxa10</i>	Mm00433966_m1	<i>Hoxc12</i>	Mm00807029_m1
<i>Hoxa11</i>	Mm00439360_m1	<i>Hoxc13</i>	Mm00802798_m1
<i>Hoxa13</i>	Mm00433967_m1	<i>Hoxc4</i>	Mm00442838_m1
<i>Hoxa2</i>	Mm00439361_m1	<i>Hoxc5</i>	Mm00433971_m1
<i>Hoxa3</i>	Mm01326402_m1	<i>Hoxc6</i>	Mm01307713_m1
<i>Hoxa4</i>	Mm01335255_g1	<i>Hoxc8</i>	Mm00439369_m1
<i>Hoxa5</i>	Mm04213381_s1	<i>Hoxc9</i>	Mm00433972_m1
<i>Hoxa6</i>	Mm00550244_m1	<i>Hoxd1</i>	Mm00439370_g1
<i>Hoxa7</i>	Mm00657963_m1	<i>Hoxd10</i>	Mm00442839_m1
<i>Hoxa9</i>	Mm00439364_m1	<i>Hoxd11</i>	Mm02602515_mH
<i>Hoxb1</i>	Mm00515118_g1	<i>Hoxd12</i>	Mm01962622_s1
<i>Hoxb13</i>	Mm00433968_m1	<i>Hoxd13</i>	Mm00433973_m1
<i>Hoxb2</i>	Mm04209931_m1	<i>Hoxd3</i>	Mm00439371_m1
<i>Hoxb3</i>	Mm04182289_s1	<i>Hoxd4</i>	Mm01333847_g1
<i>Hoxb4</i>	Mm00657964_m1	<i>Hoxd8</i>	Mm03016337_m1
<i>Hoxb5</i>	Mm00657672_m1	<i>Hoxd9</i>	Mm00442840_m1

## Supplementary Table 6

### Primer sequences used in this study

Primer	Direction	Used for	Sequence 5'-3'	Source
<i>Hoxb1</i>	F	qPCR	GGCAGGAGTTGGGAAATGTA	Kondrashov et al. 2011
<i>Hoxb1</i>	R	qPCR	GGCTGACTCCAGATCAAAGC	Kondrashov et al. 2011
<i>Hoxb8</i>	F	qPCR	TGCGCCCCAATTATTATGAC	Kondrashov et al. 2011
<i>Hoxb8</i>	R	qPCR	TTCTGCTGGTAGGGAGCTGT	Kondrashov et al. 2011
<i>Hoxc8</i>	F	qPCR	TTTGGTTCCAGAATCGAAGG	Kondrashov et al. 2011
<i>Hoxc8</i>	R	qPCR	GGGGGCTGATTTTCTCTCTC	Kondrashov et al. 2011
<i>Hoxd13</i>	F	qPCR	CGACATGGTGTCCACTTTTG	Kondrashov et al. 2011
<i>Hoxd13</i>	R	qPCR	TGGTGTAAGGCACCCTTTTC	Kondrashov et al. 2011
<i>Hoxc9</i>	F	qPCR	ACGTGGACTCGCCTCATCTCT	Kondrashov et al. 2011
<i>Hoxc9</i>	R	qPCR	GCCGTAAGGGTGATAGACCA	Kondrashov et al. 2011
<i>Hoxd12</i>	F	qPCR	GCATGAAACAGGAGCCTAGC	Kondrashov et al. 2011
<i>Hoxd12</i>	R	qPCR	CCTTCTCTCTCGAGAGTG	Kondrashov et al. 2011
<i>Sox1</i>	F	qPCR	CACCGCTACGACATGGGC	In-house
<i>Sox1</i>	R	qPCR	TAAGGGATGCCCGCTAG	In-house
<i>Sox2</i>	F	qPCR	GCACATGAACGGCTGGAGCAACG	In-house
<i>Sox2</i>	R	qPCR	TGCTGCGAGTAGGACATGCTGTAG	In-house
<i>Tbra</i>	F	qPCR	GGCTGTTGGGTAGGGAGTCA	In-house
<i>Tbra</i>	R	qPCR	GGAACATCCTCCTGCCGTTCTT	In-house
<i>Hoxc12</i>	F	ISH Probe	GAAATGGGCGAGCATAATCTCC	In-house
<i>Hoxc12</i>	R	ISH Probe	CTCCACCAAGGCAAGCTTAGTC	In-house
<i>Hoxd12</i>	F	ddPCR	ACTTTTCCAACCTGAGAGCC	In-house
<i>Hoxd12</i>	R	ddPCR	CGGTCAAGTAAGGCTGAGAG	In-house
<i>Hoxd12</i>	Probe	ddPCR	/56-FAM/ TGCACCCCT /ZEN/ GCGCAGCCTGC /3IABkFQ/	In-house
<i>Rpp30</i>	F	ddPCR	CTTTGAACCTGTCTATGGTCCT	In-house
<i>Rpp30</i>	R	ddPCR	GCATCAAATTGAGGGCATTG	In-house
<i>Rpp30</i>	Probe	ddPCR	/5-HEX/ TGTGTACCT /ZEN/ TCTCATCGTTGCATC /3IABkFQ/	In-house